Survival outcomes for patients treated in the second-line vs third-line or later settings. (A-B) Kaplan-Meier estimates of PFS (A) and OS (B) for patients treated with axi-cel, tisa-cel, or liso-cel in the third-line or later setting. (C-D) Kaplan-Meier estimates of PFS (C) and OS (D) for patients treated in the second-line setting. Differences in survival were assessed using the log-rank test. Median OS and PFS in months and HRs of the univariable Cox regression model are superimposed. HRs after adjusting for confounders in MVAs and 1- or 2-year survival probabilities are shown on the graph. MVAs could not be performed for OS in the second-line setting due to insufficient events.